$19.79
▲ +4.7% Today
as of Jul 22, 16:47 ET
Last 30 days
Recent Press Releases & News
CAPR Stock Hits Over 4-Month Low: Capricor Execs Cash In $1.5M As FDA Sets Stage For DMD Drug Review
Capricor Therapeutics Gets FDA Advisory Panel Meeting for Duchenne Therapy
Capricor’s Positive 5-Year Data For DMD Treatment Comes With A Regulatory Catch – CAPR Stock Slides 11%
Overview
52-week range
$4.30
$40
43% of range
Avg surprise (last 3)
-28.9%
Avg reaction (last 2)
+0.7%
50% positive
Latest IV / EM
327%
EM ±74.8% · $19 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue May 12, 2026 | Mar/2026 | $-0.59 | $-0.55 | -7.3% | -11.3% | -1.2% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.54 | — | — | — | — | financials |
| Mon Aug 11, 2025 | Jun/2025 | $-0.57 | $-0.48 | -18.8% | — | — | earnings |
| Tue May 13, 2025 | Mar/2025 | $-0.53 | $-0.33 | -60.6% | — | +2.7% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.38 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.35 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.31 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.25 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.29 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Mon Aug 10, 2026 | Jun/2026 | OTHER | -$0.58 | -$0.57 | -1.8% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | $2M | $4M |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-37M | — | $-26M | $-28M | $-25M | — | $-13M | $-12M |
| Net income | $-34M | — | $-25M | $-26M | $-24M | — | $-13M | $-11M |
| EPS (diluted) | $-0.59 | — | $-0.54 | $-0.57 | $-0.53 | — | $-0.38 | $-0.35 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $105M | $288M | $20M | $23M | $29M | $11M | $68M | $11M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $283M | $323M | $101M | $124M | $146M | $163M | $86M | $31M |
| Total assets | $326M | $356M | $126M | $134M | $154M | $170M | $93M | $38M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $48M | $50M | $43M | $29M | $26M | $25M | $25M | $27M |
| Total equity | $279M | $306M | $84M | $105M | $128M | $145M | $68M | $12M |